Consent to the publication of patient information: Incompetent patients may pose a problem (letter) by Newson, A.J.
Consent to the publication of patient information
Incompetent patients may pose a problem
Editor—The BMJ ethics committee’s
revised policy on consent to the publication
of patient information is laudable,1 but an
important matter remains overlooked: pub-
lishing cases involving incompetent patients.
Much can be learnt from these cases; be it
highlighting clinical difficulties or drawing
attention to neglected moral issues. But the
guidelines as written may make it impossible
to publish them.
Imagine I wished to pub-
lish a case involving a trace-
able adult with learning dis-
ability who had requested
genetic counselling. Turning
to the guidelines, I would be
required to obtain her con-
sent before publication.
However, obtaining written
informed consent from
adults with questionable
competence could be diffi-
cult or exploitative, as they
may lack the capacity to
understand the implications
of consent to publication. Furthermore, the
exceptions listed under point 3 do not apply.
Merely anonymising her information would
be ethically problematic, as could drafting a
fictional case “inspired” by the clinical
encounter. Until the mental capacity bill
becomes law, no one can provide consent on
her behalf. How should we balance the value
gained from publishing these cases with
respecting the interests of the people
involved?
Rogers and Draper have already
addressed this issue in the context of
medical ethics research and teaching.2 They
argue that using cases with practical
obstacles to obtaining consent can often be
justified by an appeal to public interest
arguments, such as the public’s right to know
what clinical and ethical dilemmas doctors
face.
Although more discussion is required,
the BMJ ethics committee also needs to
develop practical recommendations for the
use of case studies where the subject cannot
provide full informed consent.
Ainsley J Newson postdoctoral associate in clinical
ethics and genetics
Medical Ethics Unit, Imperial College London and
London IDEAS Genetics Knowledge Park, London
W6 8RP
a.newson@imperial.ac.uk
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More on confidentiality and case material
Editor—We welcome the views of the BMJ
ethics committee.1 In an article for the Journal
of Medical Ethics we drew attention to some of
the obstacles to gaining consent for publica-
tion of case material in ethics.2 We also
reviewed the policy of several general medical
and specialist ethics journals
and found that many, includ-
ing the Journal of Medical Eth-
ics, gave no instructions on
confidentiality.
Given the amount of case
material that is used in medi-
cal ethics, this is a serious
problem that editors may be
addressing in any one of sev-
eral ways: editors recognise
the problems highlighted
both in our article and in this
one and exercise discretion
on what to publish; editors
do not think that issues of confidentiality are
raised when (apparently) anonymised case
studies are used; editors have not given suf-
ficient thought to the matter and have no
policy; or, editors did not recognise the
issue. We were pleased to read that the BMJ
recognises the problem and the need for
editorial discretion in difficult cases.
Two issues are not addressed in the
article by Singer.
Firstly, it may not be possible to
anonymise a case when the relevant ethical
issues tend to make it unique. To cover this
possibility, it may be worth revising BMJ
policy point 3 (ii) to add the public interest
in debating important ethical issues to the
existing two criteria of clinical lesson or
public health.
Secondly, as Newson notes (previous let-
ter),3 the article makes no reference to the
problems of gaining consent for those who
are unable to consent for themselves. In our
paper, we pointed out that publication is
rarely in the patient’s own interest (although
involving an ethicist in discussions about the
patient might be),2 so that it is difficult to see
the grounds on which consent could be
given—except perhaps that it is not against
the interests of the patient.
Finally, on the question of reporting
mistakes, here the issue might not just be
one of the patient’s consent. What of others
involved? What if the mistake was not made
by the person hoping to publish the article
but by a colleague or associate? In such
cases, should the author gain the consent of
other relevant parties? If not, why not? And
if not, could the principles for not gaining
consent be applied to other cases—for
example, those where the patient does not
wish to give consent?
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Seeking consent is morally essential
Editor—Singer writes: “For this reason, you
must obtain express consent from patients
before publishing personal information
about them as individuals in media to which
the public has access, for example in
journals or text books, whether or not you
believe the patient can be identified. Express
consent must therefore be sought to the
publication of, for example, case-histories
about, or photographs of, patients.
“However, the GMC does admit of
exceptions in the case of patients who have
died.”1
About three years ago I found that my
son’s rare heart malformations were written
up in a cardiology surgery journal. As I come
from a medical family, I had no regrets that it
had been done. However, it was immediately
identifiable to me because he had an absent
right subclavian artery, an interrupted aortic
arch, ventricular septal defect, patent ductus
arteriosus, atrial septal defect. I knew it was
him, but I was not asked for my consent for its
release, which I would have readily agreed. It
was right that it was written about in the
literature because it was rare. It was the lack of
consent, however, that bothered me.
I disagree with the exceptions in cases
where patients have died. My son has since
died from subaortic stenosis, endocarditis,
stroke, and congestive heart failure. I would
have hoped that the sensitive nature of his
case meant that I would be informed of any
publication by any of the hospitals involved.
Although I would probably have agreed to
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publication, I would also have liked to know
what was written before suddenly finding it
on the internet.
Over the years, I have found many
untruths about me in notes and about the
condition as a whole. I would like the facts
spelt out properly—the word stereotyping
comes to mind.
My son and I both have the same rare
genetic deletion and syndrome, and it would
not surprise me at all if we were “written up”
at some stage in the future. Photographs can
also cause distress for medical families. We
are easily identifiable, but I would like to be
asked and I would in turn fully support a
doctor who in turn would write “a true and
honest report,” rather than what he or she
seemed to think at the time.
Fiona M Woollard personal assistant
York YO24 1EP
woollard@mac.com
Competing interests: None declared.
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People with intellectual
disabilities
Emotional needs of children with
intellectual disabilities are unidentified
Editor—Cooper et al discuss the differing
needs of people with intellectual disabilities.1
In recent years health policy documents
highlighting the needs of children with
intellectual disabilities have been many.
Although they recognise the different physi-
cal and emotional needs of these children,
little is known about this deprived and
disadvantaged group.
Intellectual disability has traditionally
been an exclusion criterion in research stud-
ies. At one time, clinical lore believed that
children with intellectual disability did not
have behavioural problems and that any
inappropriate behaviour displayed was sec-
ondary to their mental handicap. This view
is not supported by current evidence, recent
studies having shown that they are prone to
emotional and behavioural problems.2
These are, however, often underdiagnosed
because of issues such as “diagnostic
overshadowing,” the tendency of clinicians
to overlook additional psychiatric diagnosis
once intellectual disability has been diag-
nosed,3 and “masking,” whereby clinical
characteristics of emotional and behavioural
problems are masked by a cognitive,
language, or speech deficit.4
Research in children with intellectual
disabilities is hindered as most studies do
not use standardised diagnostic interviews
or criteria, and they are excluded from virtu-
ally all treatment studies. This has ethical
implications as little is known about diagno-
sis in and treatment of these children, and
they are often undiagnosed and untreated.
Further inequalities need to be prevented,
and attempts are required to promote high
quality research into this disadvantaged
group.
Alka S Ahuja specialist registrar in child and
adolescent psychiatry
University Hospital of Wales, Cardiff CF14 4XN
AhujaAS@Cardiff.ac.uk
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People registered disabled with learning
difficulties tend to fall through the net
Editor—Few of the findings, recommenda-
tions, and services being developed for peo-
ple with learning disabilities, as discussed by
Cooper et al,1 are being applied to people
who are registered disabled with learning
difficulties. This group seems to fall through
the net in today’s NHS; there is little to help
them, even when progress has been made
for intellectually disabled people in general.
Many adults with learning difficulties
have common health problems that have
not been addressed.2 3 In many cases neither
learning disability services nor mental
health services, including the voluntary
sector, consider this group of patients to be
appropriate for referral, assessment, or
treatment. Few agencies deal specifically
with learning difficulties. My discussions
with adults with learning difficulties indicate
that they are at a loss about where to turn for
help or advice as any existing support
groups are inevitably small, fragmented, and
uninfluential in professional circles.
General practitioners also do not know
where to refer such patients. The end result
is that few treatment options for specialist
attention are open to them even when iden-
tified medical problems require specialist
intervention because of the learning difficul-
ties. This in turn leads to inappropriate
referrals and wasted NHS consultation time.
An example is substance misuse and
eating disorders (and obesity) among people
with attention deficit disorder. Between 25%
and 50% of adults with the disorder use
alcohol and other drugs, including food, to
soothe their symptoms.4 5 However, adults
with untreated symptoms of attention deficit
disorder are often assessed by mental health
services rather than specialist learning
difficulty services in the United Kingdom.
Alarmingly, these people commonly have
five or more different diagnoses over time,
depending on which team is assessing them.
This has obvious implications for the
consistency of their treatment and the
credibility of their diagnoses.
Kiersten L Cornwell primary care development
manager
RCT Local Health Board, Treforest Industrial
Estate, Pontypridd CF37 5YR
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Feeding tubes in dementia: is
there an effective UK strategy?
See also News p 873
Editor—In their quality improvement
report Monteleoni and Clark showed a
reduction in the number of gastrostomy
tubes inserted (in patients with dementia)
after specific quality interventions had been
implemented.1 We would like to add two
points to the debate.
Firstly, how applicable is this observation
to the United Kingdom? We have previously
reported a high mortality in patients with
dementia who have a percutaneous endo-
scopic gastrostomy (PEG) tube inserted.2 As a
result of this observation we devised a prag-
matic strategy to try to improve all aspects of
our selection process for insertion of the tube.
Our quality interventions are not dissimilar to
Monteleoni and Clark but also incorporated
a one week, waiting list policy before the tube
was inserted (box). We found that this addi-
tional quality intervention further improved
selection of patients as it provided an oppor-
tunity for all those involved in the decision
making process to reflect on the implications
of PEG tube insertion. The nature and long
term implications of a decision to feed mean
that carers and relatives have to come to
terms with the decision.
In addition, particularly ill patients may
succumb during this cooling off period. Like
Monteleoni and Clark (but in a UK setting)
we were able to show a reduction in the
number of PEG tubes inserted in patients
with dementia.3
The final issue, which is perhaps harder
to quantify, is the practice by nursing homes
to accept preferentially patients with PEG
tubes. This practice is linked to a greater
amount of remuneration.4 5 In addition, the
insertion of a PEG tube may potentially
reduce the length of stay in hospital and
alleviate the pressure on acute medical beds.
Referral strategy for percutaneous
endoscopic gastrostomy3 4
• Standardise PEG referral form
including concomitant disease
• Endoscopy nurse triage and
dissemination of published evidence
• Gastroenterological review where
necessary
• Holistic and multidisciplinary
approach
• Advise against PEG feeding in
patients with dementia
• One week waiting list policy
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However, these external economic and
logistic forces may not be in the patient’s
best interest.4 5 In the United Kingdom at
least, it is only when this practice is
addressed that we will see a global decline in
referral for gastrostomy insertion in patients
with dementia.
D S Sanders consultant gastroenterologist
d.s.sanders28@btopenworld.com
Royal Hallamshire Hospital, Sheffield S10 2JF
Karna D Bardhan consultant physician
Rotherham District General Hospital, Rotherham
S60 2UD
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Liver toxicity and pioglitazone
Data are missing
Editor—The interesting drug point by
Farley-Hills et al, on fatal liver failure associ-
ated with pioglitazone, is missing data.1 I
hope that it will remind doctors to monitor
liver function and not cause a scare similar
to that which occurred with troglitazone.2
Farley-Hills, for example, did not men-
tion a liver function test before treatment with
pioglitazone was started or whether the
profile of the liver functions test was
monitored after that. The guidance from the
National Institute for Clincial Excellence
(NICE) and British National Formulary both
recommended that, as do the manufacturers.3
No details about glycaemic control were
given before blaming the patient’s diabetes
for his severe liver failure.Was there any reac-
tion to gliclazide before, such as an abnormal
liver function test, because gliclazide has been
reported before to cause liver derangement?
It seems from the patient’s histopathol-
ogy report that he had chronic liver disease
accompanied by fibrosis. Either the clinician
failed to follow the guidelines or the screen-
ing test for liver function is not robust
enough to pick up such disorder and
consequently avoid thiazolidinediones.
Peshraw Amin consultant endocrinologist
Derby Royal Infirmary Hospital, Derby DE1 2QY
peshakan@hotmail.com
Competing interests: PA has given lectures that
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Author’s reply
Editor—The liver function tests before start-
ing treatment with pioglitazone gave normal
results apart from a bilirubinmeasurement of
20 and an alanine aminotransferase concen-
tration of 44. His glycated haemoglobin con-
centration was 8.6, and there was no evidence
of a previous reaction to gliclazide.
I agree that monitoring of liver function
tests is mandatory but, in this case, liver dis-
ease was not found before treatment was
started.
As Amin says, given the histopathology
report, a more robust test of liver function
may have uncovered unsuspected disease. In
addition, perhaps the first liver function test
check after starting treatment should be
sooner than the two months recommended
by the National Institute for Clinical
Excellence.
Ed Farley-Hills consultant in anaesthetics and
intensive care
Ysbyty Gwynedd Hospital, Penrhosgarnedd,
Bangor LL57 2PW
Edward.Farley-Hills@nww-tr.wales.nhs.uk
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Best estimates of coronary risk
of passive smoking are needed
Editor—Whincup et al show passive inhala-
tion of environmental tobacco smoke to be
an unexpectedly strong risk factor for coro-
nary heart disease, when assessed using
serum cotinine concentrations, in contrast
to Enstrom and Kabat, who did not.1 2 They
emphasise the need for further prospective
studies using biomarkers.
We measured serum cotinine concentra-
tion and other biomarkers of smoking at
baseline in our Scottish heart health study
and Scottish MONICA surveys and recently
reported cardiovascular mortality in never
smokers, finding excess risk with passive
smoking3 4; preliminary work has now been
extended to include morbidity and mortality
at 16 years.
Using biomarkers and questionnaire
results we found discrepancies between
self-reported exposure and serum cotinine
concentration in passive smoking.3 Cotinine
results are affected by individual differences
in nicotine metabolism and by time delays
from exposure. Because of this we have found
a combination score of grades of self-
reported exposure and of cotinine valuable.4 5
Campaigners against tobacco tend to
talk-up positive results on passive smoking
and to discount weak or negative ones as
“flawed” for non-scientific reasons. To obtain
the best overall estimates of risks of
exposure to smoke without bias is impor-
tant. Nicotine itself is unlikely to be
responsible for the risk of passive smoking,
but cotinine is a useful biomarker of a
recently common, now disappearing, form
of smoke exposure. Banishing the tradi-
tional clouds of tobacco smoke forever may
be dear to the hearts of many of us for social
as well as medical reasons, but were any
exposure to smoke from combustion of veg-
etable matter, however caused, to be labelled
dangerous this might have severe long term
occupational and economic consequences.
It is important for that reason to get the best
estimates of risk that we can.
Ruoling Chen honorary senior lecturer
Department of Epidemiology and Public Health,
University College London, London WC1E 6BT
Ruoling.Chen@Westminster-pct.nhs.uk
Hugh Tunstall-Pedoe professor of cardiovascular
epidemiology
Roger Tavendale biochemist
Cardiovascular Epidemiology Unit, Institute of
Cardiovascular Research, University of Dundee,
Ninewells Hospital, Dundee DD1 9SY
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Salt tax could reduce
population’s salt intake
Editor—Eaton’s news item on the campaign
to reduce salt intake by the UK’s food safety
watchdog describes processed foods as a key
factor in high population salt intakes.1 A
comparatively simple way to reduce the use
of salt by manufacturers of processed food
would be to introduce a salt tax.
The potential public health and eco-
nomic benefits of a salt tax as part of a range
of interventions reducing salt has been iden-
tified in modelling work.2 Good evidence
exists around the impact of existing excise
taxes on protecting public health from
tobacco related harm and alcohol misuse.3 4
Furthermore, the revenue from a salt tax
could be used to fund information initiatives
on nutrition or to subsidise an expansion of
programmes that provide nutritious foods
(such as fresh fruit) to schoolchildren. Such
uses of the tax revenue would also be impor-
tant to ensure public acceptability of a salt tax.
Nick Wilson senior lecturer (public health)
Wellington School of Medicine and Health
Sciences, Otago University, Wellington, New
Zealand
nwilson@actrix.gen.nz
Competing interests: None declared.
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The three paradoxes of private
medicine
Hypocrisy, shock, and embarrassment
were trivialised
Editor—I read the personal view column
always with interest, mostly with pleasure,
sometimes with sadness, but rarely with the
mixture of disbelief and anger I experienced
about “The three paradoxes of private
medicine.”1
Firstly, the opening paragraphs reveal
hypocrisy usually heard from Labour politi-
cians who defend sending their children to
private schools. So private medicine stinks,
but, when it suits my family I am going to
make use of it.
Secondly, it was hard to believe how
shocked Longley was to be faced with
courtesy and politeness by the staff he
encountered. What does this say about the
NHS? In my general practice we employ 34
staff and spend time training them to deal
with the general public in a polite and
sensitive way—not always an easy task—and I
hope not with the same contempt Longley
aims at the private sector.
Finally, he faced the embarrassment of
being asked to pay for private treatment.
What did he expect to happen, and how did
he expect it to take place? Would he have
preferred to pass cash across the desk to his
consultant, or maybe, as a fellow doctor, was
he hoping to be let off?
In the same issue there was a deeply
moving and thoughtful account of the hard-
ships faced by patients in the south
Caucasus.2 Alongside this the personal view
column reeked of smug middle class angst.
Please, no more hypocrisy, shock, and
embarrassment trivialised in this way.
John A Bailey general practitioner
Whiteladies Health Centre, Bristol BS8 2PU
drjohnbailey@hotmail.com
Competing interests: None declared.
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Private medicine stinks
Editor—Longley is a man after my own
heart. His personal view on private medicine
is gloriously disputatious, and he has it bang
to rights.1 I received an unctuous letter on
embossed paper recently that declared
“What a pleasure it was to meet your charm-
ing patient Mrs X . . . I think she has Y, but for
the sake of completeness, I have ordered a
number of (expensive) tests and will see her
shortly with the results. In the meantime I
suggest she takes Zamzam XL and Zipzip
MR.”
I see Mrs X a couple of days later as an
emergency because Zamzam and Zipzip are
too expensive for her to buy privately and
would I please prescribe same instead (non-
generically of course)? I feel angry and
manipulated.
Two weeks later the second letter
arrived. It’s been a triumph for Zamzam, and
the impoverished Mrs X is now to be slotted
nicely back into the NHS.
It happened again yesterday.
James N Hardy general practitioner principal
Bethnal Green Health Centre, London E2 6LL
james.hardy@nhs.net
Competing interests: None declared.
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The golden dustman cometh
Editor—When I was a lad, a visit to the gen-
eral practitioner cost a guinea (Australian),
the radio plays came from the BBC (using
Australian actors assuming British accents),
England was still Home, at least to the older
generation, and my reading was all W E
Johns and Frank Richards. During my stud-
ies, Davidson, Hutchinson, and Hamilton
Bailey painted a world view of medicine
(admittedly somewhat Dickensian), which I
absorbed and which left me feeling that,
somehow, I understood the British way.
I thought I knew a bit about the NHS
too, but when I read Longley’s lament over
receiving some politeness and prompt treat-
ment, I realised that I knew nothing.1 I was
looking into the Heart of Whatness. This is
the great British inscrutability. They are
Frenchmen with whom we just happen to
share a common language.
How, I wondered, can one put into
words what the NHS means to Longley and
these foreigners? And then I remembered
that Dickens had done just that in Our
Mutual Friend.2 Here, Mr Nicodemus Boffin,
a praeternaturally wise and generous work-
ing man, has inherited a vast fortune derived
from recycling household waste and uses
this wealth to do good works. In Boffin’s dust
mounds great masses of waste and decay are
miraculously transformed into gold. I felt
much better for having this insight, but I
remembered also that ultimately the carts
arrived and toiled night and day, until the
mounds were all gone.
James F R Love consultant physician
217 Wickham Terrace, Brisbane, Qld 4000, Australia
jim.love@craigston.com.au
Competing interests: None declared.
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Summary of responses
Editor—The online debate of Longley’s
personal view starts with criticism of the
author, followed by attempts to understand
his rationale and psychology and a general
discussion of public and private healthcare
systems and their political implications,
ending with examples—positive and
negative—of the results of their coexistence.1
Most correspondents take issue with
Longley’s three paradoxes: paying for health
care can be disempowering, private medicine
does not seem to cost anything, and the joy of
clinical resolution is tainted by shameful feel-
ing of compromise and guilt. Many find
nothing wrong with paying for private medi-
cine, but if someone doesn’t like it, he or she
doesn’t have to do it, as “not everyone is cut
out to travel.” Payment for service is not a rea-
son to suspect ulterior motives in staff—after
all, even staff in the public sector are
motivated by money, in the shape of a salary.
Several correspondents try to analyse
where Longley’s feelings of guilt might
originate. The fact that the UK population
has become used to poor service since the
second world war—and that this attitude is
endemic—is one candidate. On the whole,
correspondents agree that hypocrisy is
worse than shame or guilt, and some point
their fingers at the author for this.
One correspondent illustrates with her
own experience that the NHS is not worse
than private care; another reminds us that
Longley would have reached the reverse
conclusion—private care is no better than
the NHS—if his expensive private consulta-
tion had resulted in a year long wait till the
next appointment. And a third rightly points
out that it’s not NHS care that is poor but
access to it.
A US practitioner asks why it is
acceptable to be taxed for care and have to
pay again to get decent customer service
and, further, why every patient should not
have the choice that paying with real money
brings. A general practitioner from South-
ampton reminds us that certain essentials in
life—housing, food, water, clothing—are not
free either, so why expect something less
essential to be?
Two correspondents illustrate with
examples what is intrinsically wrong with
private medicine in the United Kingdom: it
enables people with money to jump the
queue before being put back into the public
system. This may be a serious drain on
resources, but it also begs the question
whether anyone with money or initiative, or
both, should have that advantage.
In contrast, Switzerland and France are
cited as examples of countries where a com-
bination of private and public systems works
well, and a London based fertility specialist
explains how private and public medicine
together have advanced medical research in
the United Kingdom. Maybe another US
doctor has a point when he says that Long-
ley should celebrate the strengths of both
systems instead of shedding crocodile tears?
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